Parathyroid hormone (1-34) (human): Atomic Mechanistic Insights for Bone and Kidney Research

Executive Summary: Parathyroid hormone (1-34) (human) is a synthetic peptide fragment corresponding to the N-terminal 34 amino acids of the endogenous hormone, with a molecular weight of 4117.72 Da and sequence H2N-SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF-OH. This reagent binds parathyroid hormone 1 and 2 receptors (PTH1R/PTH2R), stimulating cAMP and inositol phosphate signaling with an IC₅₀ of 0.22 nM in human kidney 293 cells (Huang et al., 2025). Its actions regulate serum calcium via coordinated effects on bone, kidney, and intestinal physiology. In vivo, PTH (1-34) increases trabecular and cortical bone mass in rodents, supporting its widespread use in bone metabolism and osteoporosis research (APExBIO). High solubility in DMSO (≥399.3 mg/mL) and water (≥19.88 mg/mL), as well as stability when stored desiccated at -20°C, ensure experimental reliability. This article integrates the latest organoid and assembloid research to clarify its mechanistic and translational value.

Biological Rationale

Parathyroid hormone (1-34) (human) (PTH (1-34)) is derived from the N-terminal region of the full-length human parathyroid hormone, which is secreted by chief cells in the parathyroid glands. The peptide fragment preserves the biologically active domain responsible for receptor binding and downstream signaling. Its main physiological function is to maintain serum calcium concentration within a narrow range, a process critical for neuromuscular excitability, bone mineralization, and enzymatic activity (APExBIO). PTH (1-34) exerts its effects by acting as a parathyroid hormone 1 receptor agonist and is instrumental in research on bone metabolism, osteoporosis, and calcium homeostasis (see related article; this article details the latest integration with advanced assembloid models). The peptide is also relevant to kidney research, as it regulates renal reabsorption of calcium and magnesium, critical components in kidney disease and regeneration studies (Huang et al., 2025).

Mechanism of Action of Parathyroid hormone (1-34) (human)

PTH (1-34) (human) binds to the parathyroid hormone 1 receptor (PTH1R) and, to a lesser extent, the parathyroid hormone 2 receptor (PTH2R), both of which are class B G protein-coupled receptors. Upon receptor engagement, the peptide activates intracellular signaling cascades, notably the cyclic AMP (cAMP) and inositol phosphate pathways. In human embryonic kidney 293 cells transfected with PTH1R, PTH (1-34) induces cAMP accumulation with an IC₅₀ of 0.22 nM, demonstrating high potency (APExBIO). The downstream effects include:

• Stimulation of osteoclast-mediated bone resorption, increasing calcium release from skeletal stores.
• Upregulation of active vitamin D (calcitriol) synthesis in renal proximal tubules, thereby enhancing intestinal calcium absorption.
• Promotion of calcium and magnesium reabsorption in the distal tubules and thick ascending limb of the nephron.
• Activation of inositol phosphate turnover, further modulating cellular responses.

These concerted actions place PTH (1-34) at the core of calcium homeostasis regulation and make it a preferred agent for in vitro and in vivo studies of bone and kidney physiology (compare: deeper mechanistic insights in kidney/osteoporosis models).

Evidence & Benchmarks

• PTH (1-34) (human) stimulates cAMP production in PTH1R-transfected human kidney 293 cells with an IC₅₀ of 0.22 nM (APExBIO).
• In vivo, daily subcutaneous administration of 10 or 40 μg/kg in male Fisher 344 rats significantly increases trabecular and cortical bone mass in a dose- and time-dependent manner (APExBIO).
• Solubility of PTH (1-34) is ≥399.3 mg/mL in DMSO and ≥19.88 mg/mL in water, with no detectable solubility in ethanol (APExBIO).
• Human kidney assembloid studies highlight the utility of PTH (1-34) in modeling high-fidelity renal physiology, with robust receptor-mediated signaling responses observed in spatially patterned nephron systems (Huang et al., 2025).
• PTH (1-34) upregulates vitamin D activation, facilitating increased intestinal calcium absorption and contributing to systemic calcium homeostasis (APExBIO).

Applications, Limits & Misconceptions

PTH (1-34) (human) has established roles in basic and translational research. Its major applications include:

• Bone metabolism research, particularly modeling osteoporosis and evaluating anabolic/catabolic bone responses.
• Advanced kidney research, including use in kidney organoids and assembloids that recapitulate human nephron development and function (Huang et al., 2025).
• Studies of calcium and magnesium transport, as well as downstream effects on vitamin D metabolism.
• Pharmacological validation of PTH/PTHrP receptor signaling pathways and cAMP/intracellular signaling analysis.

This article extends previous discussions (e.g., Reliable Solutions for Laboratory Modeling) by integrating evidence from new assembloid disease models and benchmarking peptide stability and purity.

Common Pitfalls or Misconceptions

• Misconception: PTH (1-34) is suitable for therapeutic or diagnostic use.
  Clarification: This product is for research use only and is not approved for clinical applications (APExBIO).
• Misconception: Ethanol can be used as a solvent.
  Clarification: PTH (1-34) (human) is insoluble in ethanol; DMSO or water (with noted maximum concentrations) must be used instead.
• Misconception: Long-term storage of peptide solutions is acceptable.
  Clarification: Solutions should be freshly prepared; long-term storage can compromise stability and activity.
• Misconception: The peptide's activity is non-specific.
  Clarification: Activity is receptor-mediated and highly specific to PTH1R/PTH2R, as demonstrated in transfected cell and organoid models.
• Misconception: All in vivo models respond identically.
  Clarification: Dose-response and bone mass effects are model- and sex-dependent; experimental details must be matched to the study system (Huang et al., 2025).

Workflow Integration & Parameters

PTH (1-34) (human) (SKU A1129) is supplied as a high-purity (>97.8%) solid. For optimal results:

• Reconstitute in DMSO (≥399.3 mg/mL) or water (≥19.88 mg/mL), avoiding ethanol.
• Store aliquots desiccated at -20°C to preserve activity.
• Prepare fresh working solutions for each experiment; avoid repeated freeze-thaw cycles.
• Recommended concentrations in cell signaling assays: sub-nanomolar to nanomolar range (e.g., IC₅₀ for cAMP stimulation = 0.22 nM).
• For in vivo studies, follow established dose regimens (e.g., 10–40 μg/kg/day in rodents) with appropriate controls.

For advanced organoid and assembloid research, integrate PTH (1-34) in defined media to probe nephron maturation, parathyroid hormone receptor signaling, and disease modeling fidelity (Huang et al., 2025). This extends prior overviews by specifying recent protocols compatible with spatially patterned kidney assembloids (updated workflow guidance here).

Conclusion & Outlook

Parathyroid hormone (1-34) (human) is a benchmark tool for dissecting bone and kidney physiology at the molecular and cellular levels. Its validated mechanism—via cAMP and inositol phosphate signaling through PTH1R—supports reproducible modeling of calcium homeostasis, bone metabolism, and advanced organoid systems. The integration of PTH (1-34) in spatially patterned kidney assembloid models marks a significant advance for translational disease research (Huang et al., 2025). For reliable, high-purity research reagents, APExBIO's Parathyroid hormone (1-34) (human) (A1129 kit) sets the standard for mechanistic and translational studies in bone and kidney research.